There’s no firm date that Celldex Therapeutics (CLDX) is going to update the market on the progress it has made with its dense deposit disease treatment, CDX-1135, currently in Phase 2 testing. It’s just supposed to happen next month.
Whenever it happens, though, it should be big.
Dense deposit disease is a very rare kidney disease that ultimately causes kidney failure for most of its sufferers. That’s because there’s no existing treatment for it. If Celldex looks like it could be the first to bring such a treatment to the market, CLDX stock could soar on the news.
Indeed, CLDX could be one of the biggest movers among biotech stocks for the first quarter of 2014.